Therapeutic potential of tetrahydrobiopterin for treating vascular and cardiac disease

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 3, 2007, Pages 238-246

  Moens, An L ^a   Kass, David A ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

eNOS uncoupling; Superoxide; Tetrahydrobiopterin

Indexed keywords

ASCORBIC ACID; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE SYNTHASE; OXIPURINOL; PLACEBO; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TETRAHYDROBIOPTERIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; ELECTRON SPIN RESONANCE; ENDOTHELIAL DYSFUNCTION; GENE DELETION; GENE OVEREXPRESSION; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ANIMALS; BIOPTERIN; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; FOLIC ACID; HUMANS; NITRIC OXIDE SYNTHASE;

EID: 34548748213     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318123f854     Document Type: Review

References (100)

1. Kaufman S. The structure of the phenyl-alanine cofactor. Proc Natl Acad Sci USA. 1963;50:1085-1093.
2. Thony B, Auerbach G, Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem J. 2000;347:1-16.
3. Fitzpatrick PF. Tetrahydropterin-dependent amino acid hydroxylases. Annu Rev Biochem. 1999;68:355-381.
4. Danks DM, Cotton RG, Schlesinger P. Letter: Tetrahydrobiopterin treatment of variant form of phenylketonuria. Lancet. 1975;2:1043.
5. Smith I, Clayton BE, Wolff OH. New variant of phenylketonuria with progressive neurological illness unresponsive to phenylalanine restriction. Lancet. 1975;1:1108-1111.
6. 4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomized placebo-controlled study. Lancet. 2007;370:504-510.
7. Tayeh MA, Marletta MA. Macrophage oxidation of L-arginine to nitric oxide, nitrite, and nitrate. Tetrahydrobiopterin is required as a cofactor. J Biol Chem. 1989;264:19654-19658.
8. Gorren AC, Mayer B. Tetrahydrobiopterin in nitric oxide synthesis: a novel biological role for pteridines. Curr Drug Metab. 2002;3:133-157.
9. Stuehr DJ. Structure-function aspects in the nitric oxide synthases. Annu Rev Pharmacol Toxicol. 1997;37:339-359.
10. Vasquez-Vivar J, Kalyanaraman B, Martasek P. The role of tetrahydrobiopterin in superoxide generation from eNOS: enzymology and physiological implications. Free Radic Res. 2003;37:121-127.
11. Moens AL, Kass DA. Tetrahydrobiopterin and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2006;26:2439-2444.
12. Hattori Y, Nakanishi N, Akimoto K, et al. HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:176-182.
13. Mayer B, Werner ER. In search of a function for tetrahydrobiopterin in the biosynthesis of nitric oxide. Naunyn Schmiedebergs Arch Pharmacol. 1995;351:453-463.
14. Butler IJ, Koslow SH, Krumholz A, et al. A disorder of biogenic amines in dihydropteridine reductase deficiency. Ann Neurol. 1978;3:224-230.
15. Gorren AC, Mayer B. Tetrahydrobiopterin in nitric oxide synthesis: a novel biological role for pteridines. Curr Drug Metab. 2002;3:133-157.
16. Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol. 2004;24:413-420.
17. Gorren AC, List BM, Schrammel A, et al. Tetrahydrobiopterin-free neuronal nitric oxide synthase: evidence for two identical highly anticooperative pteridine binding sites. Biochemistry. 1996;35:16735-16745.
18. Rodriguez-Crespo I, Moenne-Loccoz P, Loehr TM, et al. Endothelial nitric oxide synthase: modulations of the distal heme site produced by progressive N-terminal deletions. Biochemistry. 1997;36:8530-8538.
19. Klatt P, Schmid M, Leopold E, et al. The pteridine binding site of brain nitric oxide synthase. Tetrahydrobiopterin binding kinetics, specificity, and allosteric interaction with the substrate domain. J Biol Chem. 1994;269:13861-13866.
20. List BM, Klosch B, Volker C, et al. Characterization of bovine endothelial nitric oxide synthase as a homodimer with down-regulated uncoupled NADPH oxidase activity: tetrahydrobiopterin binding kinetics and role of haem in dimerization. Biochem J. 1997;323:159-165.
21. Wei CC, Wang ZQ, Meade AL, et al. Why do nitric oxide synthases use tetrahydrobiopterin? J Inorg Biochem. 2002;91:618-624.
22. Wei CC, Wang ZQ, Wang Q, et al. Rapid kinetic studies link tetrahydrobiopterin radical formation to heme-dioxy reduction and arginine hydroxylation in inducible nitric-oxide synthase. J Biol Chem. 2001;276:315-319.
23. Bec N, Gorren AC, Voelker C, et al. Reaction of neuronal nitric-oxide synthase with oxygen at low temperature. Evidence for reductive activation of the oxy-ferrous complex by tetrahydrobiopterin. J Biol Chem. 1998;273:13502-13508.
24. Gorren AC, Bec N, Schrammel A, et al. Low-temperature optical absorption spectra suggest a redox role for tetrahydrobiopterin in both steps of nitric oxide synthase catalysis. Biochemistry. 2000;39:11763-11770.
25. Bec N, Gorren AFC, Mayer B, et al. The role of tetrahydrobiopterin in the activation of oxygen by nitric-oxide synthase. J Inorg Biochem. 2000;81:207-211.
26. Wei CC, Wang ZQ, Wang Q, et al. Rapid kinetic studies link tetrahydrobiopterin radical formation to heme-dioxy reduction and arginine hydroxylation in inducible nitric-oxide synthase. J Biol Chem. 2001;276:315-319.
27. Baek KJ, Thiel BA, Lucas S, et al. Macrophage nitric oxide synthase subunits. Purification, characterization, and role of prosthetic groups and substrate in regulating their association into a dimeric enzyme. J Biol Chem. 1993;268:21120-21129.
28. Gorren AC, Mayer B. Tetrahydrobiopterin in nitric oxide synthesis: a novel biological role for pteridines. Curr Drug Metab. 2002;3:133-157.
29. Ghosh S, Wolan D, Adak S, et al. Mutational analysis of the tetrahydrobiopterin-binding site in inducible nitric-oxide synthase. J Biol Chem. 1999;274:24100-24112.
30. bu-Soud HM, Wu C, Ghosh DK, et al. Stopped-flow analysis of CO and NO binding to inducible nitric oxide synthase. Biochemistry. 1998;37:3777-3786.
31. Kotsonis P, Frohlich LG, Shutenko ZV, et al. Allosteric regulation of neuronal nitric oxide synthase by tetrahydrobiopterin and suppression of auto-damaging superoxide. Biochem J. 2000;346 Pt 3:767-776.
32. Reif A, Frohlich LG, Kotsonis P, et al. Tetrahydrobiopterin inhibits monomerization and is consumed during catalysis in neuronal NO synthase. J Biol Chem. 1999;274:24921-24929.
33. Vasquez-Vivar J, Whitsett J, Martasek P, et al. Reaction of tetrahydrobiopterin with superoxide: EPR-kinetic analysis and characterization of the pteridine radical. Free Radic Biol Med. 2001;31:975-985.
34. Rafferty SP, Boyington JC, Kulansky R, et al. Stoichiometric arginine binding in the oxygenase domain of inducible nitric oxide synthase requires a single molecule of tetrahydrobiopterin per dimer. Biochem Biophys Res Commun. 1999;257:344-347.
35. Pou S, Pou WS, Bredt DS, et al. Generation of superoxide by purified brain nitric oxide synthase. J Biol Chem. 1992;267:24173-24176.
36. Vasquez-Vivar J, Kalyanaraman B, Martasek P. The role of tetrahydrobiopterin in superoxide generation from eNOS: enzymology and physiological implications. Free Radic Res. 2003;37:121-127.
37. Heinzel B, John M, Klatt P, et al. Ca2+/calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J. 1992;281:627-630.
38. Klatt P, Schmidt K, Uray G, et al. Multiple catalytic functions of brain nitric oxide synthase. Biochemical characterization, cofactor-requirement, and the role of N omega-hydroxy-L-arginine as an intermediate. J Biol Chem. 1993;268:14781-14787.
39. McMillan K, Adler M, Auld DS, et al. Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc Natl Acad Sci USA. 2000;97:1506-1511.
40. Pant K, Crane BR. Structure of a loose dimer: an intermediate in nitric oxide synthase assembly. J Mol Biol. 2005;352:932-940.
41. Antoniades C, Shirodaria C, Warrick N, et al. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation. 2006;114:1193-1201.
42. Cosentino F, Patton S, d'Uscio LV, et al. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest. 1998;101:1530-1537.
43. Ozaki M, Kawashima S, Yamashita T, et al. Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J Clin Invest. 2002;110:331-340.
44. Bevers LM, Braam B, Post JA, et al. Tetrahydrobiopterin, but not L-arginine, decreases NO synthase uncoupling in cells expressing high levels of endothelial NO synthase. Hypertension. 2006;47:87-94.
45. Schulman SP, Becker LC, Kass DA, et al. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA. 2006;295:58-64.
46. Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest. 2002;109:817-826.
47. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003;111:1201-1209.
48. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993;91:2546-2551.
49. Newaz MA, Yousefipour Z, Oyekan A. Oxidative stress-associated vascular aging is xanthine oxidase-dependent but not NAD(P)H oxidase-dependent. J Cardiovasc Pharmacol. 2006;48:88-94.
50. Cardillo C, Kilcoyne CM, Cannon RO, et al. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension. 1997;30:57-63.
51. O'Driscoll JG, Green DJ, Rankin JM, et al. Nitric oxide-dependent endothelial function is unaffected by allopurinol in hypercholesterolaemic subjects. Clin Exp Pharmacol Physiol. 1999;26:779-783.
52. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006;113:1708-1714.
53. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension. 2007;49:241-248.
54. Takimoto E, Champion HC, Li M, et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest. 2005;115:1221-1231.
55. Mollnau H, Oelze M, August M, et al. Mechanisms of increased vascular superoxide production in an experimental model of idiopathic dilated cardiomyopathy. Arterioscler Thromb Vasc Biol. 2005;25:2554-2559.
56. Fiege B, Ballhausen D, Kierat L, et al. Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. Mol Genet Metab. 2004;81:45-51.
57. Sawabe K, Wakasugi KO, Hasegawa H. Tetrahydrobiopterin uptake in supplemental administration: elevation of tissue tetrahydrobiopterin in mice following uptake of the exogenously oxidized product 7,8-dihydrobiopterin and subsequent reduction by an anti-folate-sensitive process. J Pharmacol Sci. 2004;96:124-133.
58. Kaufman S. Some metabolic relationships between biopterin and folate: implications for the "methyl trap hypothesis." Neurochem Res. 1991;16:1031-1036.
59. Hyndman ME, Verma S, Rosenfeld RJ, et al. Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. Am J Physiol Heart Circ Physiol. 2002;282:H2167-H2172.
60. Kuzkaya N, Weissmann N, Harrison DG, et al. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem. 2003;278:22546-22554.
61. Patel KB, Stratford MR, Wardman P, et al. Oxidation of tetrahydrobiopterin by biological radicals and scavenging of the trihydrobiopterin radical by ascorbate. Free Radic Biol Med. 2002;32:203-211.
62. Vasquez-Vivar J, Whitsett J, Martasek P, et al. Reaction of tetrahydrobiopterin with superoxide: EPR-kinetic analysis and characterization of the pteridine radical. Free Radic Biol Med. 2001;31:975-985.
63. Walter R, Blau N, Kierat L, et al. Systemic tetrahydrobiopterin (BH4) levels and coronary artery disease. Cardiology. 2000;94:265-266.
64. Shinozaki K, Hirayama A, Nishio Y, et al. Coronary endothelial dysfunction in the insulin-resistant state is linked to abnormal pteridine metabolism and vascular oxidative stress. J Am Coll Cardiol. 2001;38:1821-1828.
65. Huang PL, Huang Z, Mashimo H, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377:239-242.
66. Shesely EG, Maeda N, Kim HS, et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 1996;93:13176-13181.
67. Ohashi Y, Kawashima S, Hirata K, et al. Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest. 1998;102:2061-2071.
68. Kase H, Hashikabe Y, Uchida K, et al. Supplementation with tetrahydrobiopterin prevents the cardiovascular effects of angiotensin II-induced oxidative and nitrosative stress. J Hypertens. 2005;23:1375-1382.
69. Podjarny E, Benchetrit S, Rathaus M, et al. Effect of tetrahydrobiopterin on blood pressure in rats after subtotal nephrectomy. Nephron Physiol. 2003;94:6-9.
70. Zhang Y, Pang T, Earl J, et al. Role of tetrahydrobiopterin in adrenocorticotropic hormone-induced hypertension in the rat. Clin Exp Hypertens. 2004;26:231-241.
71. Khoo JP, Zhao L, Alp NJ, et al. Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation. 2005;111:2126-2133.
72. Pieper GM. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J Cardiovasc Pharmacol. 1997;29:8-15.
73. Shinozaki K, Nishio Y, Okamura T, et al. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ Res. 2000;87:566-573.
74. Stroes E, Kastelein J, Cosentino F, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest. 1997;99:41-46.
75. Heitzer T, Brockhoff C, Mayer B, et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. Circ Res. 2000;86:E36-E41.
76. Higashi Y, Sasaki S, Nakagawa K, et al. Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am J Hypertens. 2002;15:326-332.
77. Heitzer T, Brockhoff C, Mayer B, et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. Circ Res. 2000;86:E36-E41.
78. Stevens LM, Fortier S, Aubin MC, et al. Effect of tetrahydrobiopterin on selective endothelial dysfunction of epicardial porcine coronary arteries induced by cardiopulmonary bypass. Eur J Cardiothorac Surg. 2006;30:464-471.
79. Stroes ES, van Faassen EE, Yo M, et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res. 2000;86:1129-1134.
80. Antoniades C, Shirodaria C, Warrick N, et al. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation. 2006;114:1193-1201.
81. Tawakol A, Migrino RQ, Aziz KS, et al. High-dose folic acid acutely improves coronary vasodilator function in patients with coronary artery disease. J Am Coll Cardiol. 2005;45:1580-1584.
82. Dragoni S, Gori T, Di Stolfo G, et al. Folic acid does not limit endothelial dysfunction induced by ischemia and reperfusion: a human study. J Cardiovasc Pharmacol. 2005;46:494-497.
83. Bazzano LA, Reynolds K, Holder KN, et al. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA. 2006;296:2720-2726.
84. Alp NJ, McAteer MA, Khoo J, et al. Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. Arterioscler Thromb Vasc Biol. 2004;24:445-450.
85. Shinozaki K, Kashiwagi A, Nishio Y, et al. Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2- imbalance in insulin-resistant rat aorta. Diabetes. 1999;48:2437-2445.
86. Cai S, Khoo J, Mussa S, et al. Endothelial nitric oxide synthase dysfunction in diabetic mice: importance of tetrahydrobiopterin in eNOS dimerisation. Diabetologia. 2005;48:1933-1940.
87. Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001;88:E14-E22.
88. Kaufman S. Metabolism of the phenylalanine hydroxylation cofactor. J Biol Chem. 1967;242:3934-3943.
89. Thum T, Fraccarollo D, Schultheiss M, et al. Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes. 2007;56:666-674.
90. Nystrom T, Nygren A, Sjoholm A. Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease. Am J Physiol Endocrinol Metab. 2004;287:E919-E925.
91. Cai S, Khoo J, Channon KM. Augmented BH4 by gene transfer restores nitric oxide synthase function in hyperglycemic human endothelial cells. Cardiovasc Res. 2005;65:823-831.
92. Tiefenbacher CP, Chilian WM, Mitchell M, et al. Restoration of endothelium-dependent vasodilation after reperfusion injury by tetrahydrobiopterin. Circulation. 1996;94:1423-1429.
93. Yamashiro S, Noguchi K, Matsuzaki T, et al. Beneficial effect of tetrahydrobiopterin on ischemia-reperfusion injury in isolated perfused rat hearts. J Thorac Cardiovasc Surg. 2002;124:775-784.
94. Verma S, Maitland A, Weisel RD, et al. Novel cardioprotective effects of tetrahydrobiopterin after anoxia and reoxygenation: Identifying cellular targets for pharmacologic manipulation. J Thorac Cardiovasc Surg. 2002;123:1074-1083.
95. Yaoita H, Yoshinari K, Maehara K, et al. Different effects of a highcholesterol diet on ischemic cardiac dysfunction and remodeling induced by coronary stenosis and coronary occlusion. J Am Coll Cardiol. 2005;45:2078-2087.
96. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
97. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension. 2003;42:1075-1081.
98. Kase H, Hashikabe Y, Uchida K, et al. Supplementation with tetrahydrobiopterin prevents the cardiovascular effects of angiotensin II-induced oxidative and nitrosative stress. J Hypertens. 2005;23:1375-1382.
99. Pant K, Crane BR. Structure of a loose dimer: an intermediate in nitric oxide synthase assembly. J Mol Biol. 2005;352:932-940.
100. Hattori Y, Hattori S, Wang X, et al. Oral administration of tetrahydrobiopterin slows the progression of atherosclerosis in apolipoprotein e-knockout mice. Arterioscler Thromb Vasc Biol. 2007;27:865-870.